KR100486057B1 - 양성자펌프억제제및프로키네틱제함유경구제약제형 - Google Patents

양성자펌프억제제및프로키네틱제함유경구제약제형 Download PDF

Info

Publication number
KR100486057B1
KR100486057B1 KR1019970706235A KR19970706235A KR100486057B1 KR 100486057 B1 KR100486057 B1 KR 100486057B1 KR 1019970706235 A KR1019970706235 A KR 1019970706235A KR 19970706235 A KR19970706235 A KR 19970706235A KR 100486057 B1 KR100486057 B1 KR 100486057B1
Authority
KR
South Korea
Prior art keywords
tablet
formulation
proton pump
pump inhibitor
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019970706235A
Other languages
English (en)
Korean (ko)
Other versions
KR19980702828A (ko
Inventor
엘렌 드퓌
아그네타 할그렌
Original Assignee
아스트라제네카 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 악티에볼라그 filed Critical 아스트라제네카 악티에볼라그
Publication of KR19980702828A publication Critical patent/KR19980702828A/ko
Application granted granted Critical
Publication of KR100486057B1 publication Critical patent/KR100486057B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019970706235A 1996-01-08 1996-12-20 양성자펌프억제제및프로키네틱제함유경구제약제형 Expired - Fee Related KR100486057B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600072-4 1996-01-08
SE9600072A SE9600072D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients II

Publications (2)

Publication Number Publication Date
KR19980702828A KR19980702828A (ko) 1998-08-05
KR100486057B1 true KR100486057B1 (ko) 2005-09-08

Family

ID=20400970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970706235A Expired - Fee Related KR100486057B1 (ko) 1996-01-08 1996-12-20 양성자펌프억제제및프로키네틱제함유경구제약제형

Country Status (29)

Country Link
US (1) US6132771A (enExample)
EP (1) EP0814840B1 (enExample)
JP (1) JPH11501949A (enExample)
KR (1) KR100486057B1 (enExample)
CN (1) CN1142792C (enExample)
AR (1) AR008750A1 (enExample)
AT (1) ATE228010T1 (enExample)
AU (1) AU712572B2 (enExample)
BR (1) BR9607344A (enExample)
CA (1) CA2214033C (enExample)
CZ (1) CZ280897A3 (enExample)
DE (1) DE69624910T2 (enExample)
DK (1) DK0814840T3 (enExample)
EE (1) EE9700195A (enExample)
ES (1) ES2185816T3 (enExample)
HU (1) HUP9904094A3 (enExample)
ID (1) ID18383A (enExample)
IL (1) IL121652A (enExample)
IS (1) IS4550A (enExample)
MX (1) MX9706769A (enExample)
NO (1) NO316425B1 (enExample)
NZ (1) NZ325976A (enExample)
PL (1) PL322176A1 (enExample)
PT (1) PT814840E (enExample)
SE (1) SE9600072D0 (enExample)
SK (1) SK117097A3 (enExample)
TR (1) TR199700917T1 (enExample)
WO (1) WO1997025065A1 (enExample)
ZA (1) ZA9610938B (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
HUP0100065A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
US20060182802A1 (en) 1998-07-28 2006-08-17 Toshihiro Shimizu Rapidly disintegrable solid preparation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
JP3667640B2 (ja) * 1999-04-01 2005-07-06 ダブリューエム リグリー ジュニア カンパニー チューインガム用の長い香味持続時間放出構造
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
AU3984101A (en) 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
KR20030011805A (ko) 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
US20040146554A1 (en) * 2000-07-15 2004-07-29 Sharma Virender K. Method for the administration of acid-labile drugs
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP2006282677A (ja) * 2001-10-17 2006-10-19 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
ES2392960T3 (es) 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
BR8300543U (pt) * 2003-04-09 2004-11-23 Medley S A Ind Farmaceutica Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte dos pacientes
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US20050059704A1 (en) * 2003-08-29 2005-03-17 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
ZA200606409B (en) * 2004-01-06 2008-06-25 Panacea Biotec Ltd Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
WO2006011638A1 (ja) * 2004-07-28 2006-02-02 Dainippon Sumitomo Pharma Co., Ltd. 複数の被覆層を有するフィルムコーティング錠
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CN101405004A (zh) * 2006-01-20 2009-04-08 大日本住友制药株式会社 新型薄膜衣片剂
EP2012756A4 (en) * 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd MULTI-UNIT COMPOSITIONS
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
US20120128764A1 (en) * 2009-02-23 2012-05-24 Aptalis Pharmatech, Inc. Controlled-release compositions comprising a proton pump inhibitor
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
CA2765635C (en) * 2009-06-25 2016-09-06 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
CA2781286A1 (en) * 2009-11-20 2011-05-26 Handa Pharmaceuticals, Llc Oral formulation for dexlansoprazole
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
WO2011126327A2 (en) * 2010-04-09 2011-10-13 Hyundai Pharm Co., Ltd. Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
WO2011136750A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Pharmaceutical compositions inducing synergistic effect
BRPI1103093A2 (pt) * 2011-06-03 2013-07-02 Eurofarma Laboratarios Ltda composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
JP6273302B2 (ja) * 2013-03-15 2018-01-31 コリア ユナイテッド ファーマ． インコーポレーテッド １日１回の投与で薬理学的臨床効果を提供するモサプリド徐放性製剤
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP2018518521A (ja) * 2015-06-26 2018-07-12 コリア ユナイテッド ファーマ． インコーポレーテッド モサプリドとラベプラゾールの複合製剤
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102034694B1 (ko) * 2017-12-14 2019-10-22 한국유나이티드제약 주식회사 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제
WO2024224407A1 (en) * 2023-04-28 2024-10-31 Akums Drugs & Pharmaceuticals Limited Multi-layer pellet formulation and process of preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) * 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
IE59287B1 (en) * 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
CA2141582C (en) * 1992-08-05 2003-09-30 Angelo Mario Morella Pelletised pharmaceutical composition
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
JP3017906B2 (ja) * 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
CA2173506C (en) * 1993-10-12 2006-05-09 Tomohisa Matsushita Enteric granule-containing tablets
GB2285989A (en) * 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
ATE206044T1 (de) * 1994-07-08 2001-10-15 Astrazeneca Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations

Also Published As

Publication number Publication date
CA2214033C (en) 2006-01-10
PT814840E (pt) 2003-04-30
HUP9904094A3 (en) 2002-03-28
NO974070D0 (no) 1997-09-04
BR9607344A (pt) 1997-12-30
NO316425B1 (no) 2004-01-26
IS4550A (is) 1997-08-21
EP0814840B1 (en) 2002-11-20
IL121652A0 (en) 1998-02-08
HUP9904094A2 (hu) 2000-06-28
TR199700917T1 (xx) 1997-11-21
MX9706769A (es) 1997-11-29
ZA9610938B (en) 1997-07-08
DK0814840T3 (da) 2003-02-24
KR19980702828A (ko) 1998-08-05
CA2214033A1 (en) 1997-07-17
CN1142792C (zh) 2004-03-24
CZ280897A3 (cs) 1998-04-15
US6132771A (en) 2000-10-17
ES2185816T3 (es) 2003-05-01
JPH11501949A (ja) 1999-02-16
DE69624910D1 (de) 2003-01-02
IL121652A (en) 2002-03-10
WO1997025065A1 (en) 1997-07-17
AR008750A1 (es) 2000-02-23
SE9600072D0 (sv) 1996-01-08
DE69624910T2 (de) 2003-09-04
CN1183049A (zh) 1998-05-27
ID18383A (id) 1998-04-02
EP0814840A1 (en) 1998-01-07
EE9700195A (et) 1998-02-16
ATE228010T1 (de) 2002-12-15
AU712572B2 (en) 1999-11-11
SK117097A3 (en) 1998-06-03
PL322176A1 (en) 1998-01-19
AU1324097A (en) 1997-08-01
NZ325976A (en) 1999-02-25
NO974070L (no) 1997-10-06

Similar Documents

Publication Publication Date Title
KR100486057B1 (ko) 양성자펌프억제제및프로키네틱제함유경구제약제형
KR100490075B1 (ko) 양성자펌프억제제및제산제또는알기네이트함유경구제약제형
KR100384961B1 (ko) 프로톤펌프억제제를함유하는다단위제약제제
EP0814783B1 (en) Multiple unit effervescent dosage forms comprising protonpump inhibitor
KR100483870B1 (ko) 양성자펌프억제제및비스테로이드성항염증약물을포함하는경구제약제형
KR100384960B1 (ko) 다단위정제투여형i
EP1043976B1 (en) Oral pharmaceutical extended release dosage form
KR20010033427A (ko) 경구용 제약학적 펄스 방출형 투여 제형
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
KR100399524B1 (ko) 신규경구제약학상제형
HK1001763B (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
HK1017993A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20090331

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100421

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100421

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000